BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 36159990)

  • 1. MJDs family members: Potential prognostic targets and immune-associated biomarkers in hepatocellular carcinoma.
    Zhou L; Chen G; Liu T; Liu X; Yang C; Jiang J
    Front Genet; 2022; 13():965805. PubMed ID: 36159990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of Rad51 as a prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma.
    Xu H; Xiong C; Chen Y; Zhang C; Bai D
    Bioengineered; 2021 Dec; 12(1):2664-2675. PubMed ID: 34115569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Dysregulation of SOX Family Correlates with DNA Methylation and Immune Microenvironment Characteristics to Predict Prognosis in Hepatocellular Carcinoma.
    Qin S; Liu G; Jin H; Chen X; He J; Xiao J; Qin Y; Mao Y; Zhao L
    Dis Markers; 2022; 2022():2676114. PubMed ID: 35465267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of chloride intracellular channels as prognostic factors correlated with immune infiltration in hepatocellular carcinoma using bioinformatics analysis.
    Huang JJ; Lin J; Chen X; Zhu W
    Medicine (Baltimore); 2021 Nov; 100(45):e27739. PubMed ID: 34766585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six Cell Cycle-related Genes Serve as Potential Prognostic Biomarkers and Correlated with Immune Infiltrates in Hepatocellular Carcinoma.
    Shi Y; Sang X; Deng J; Wang Y; Chen X; Lin S; Wu F; Xu A
    J Cancer; 2023; 14(1):9-23. PubMed ID: 36605491
    [No Abstract]   [Full Text] [Related]  

  • 6. Comprehensive analysis of prognostic value and immune infiltration of IAPs family in hepatocellular carcinoma.
    Yang X; Yu X; Nie H; Jiang W; Zhou J; Ou C; He X
    J Cancer; 2023; 14(15):2848-2866. PubMed ID: 37781078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional analysis of the expression, prognostic value and immune infiltration activities of the COMMD protein family in hepatocellular carcinoma.
    Wang X; He S; Zheng X; Huang S; Chen H; Chen H; Luo W; Guo Z; He X; Zhao Q
    BMC Cancer; 2021 Sep; 21(1):1001. PubMed ID: 34493238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significant correlation between HSPA4 and prognosis and immune regulation in hepatocellular carcinoma.
    Shang BB; Chen J; Wang ZG; Liu H
    PeerJ; 2021; 9():e12315. PubMed ID: 34754620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of therapeutic targets and prognostic biomarkers among CXC chemokines in hepatocellular carcinoma microenvironment.
    Yin Z; Ma T; Chen S; Yu M
    Cancer Biomark; 2023; 36(3):231-250. PubMed ID: 36938723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
    Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
    World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coiled-coil domain-containing protein 58 (CCDC58) is a novel prognostic biomarker correlated with mitochondrial functions in hepatocellular carcinoma.
    Chen L; Zhang J; Yang Y; Shu J; Zheng J; Zhan X; Guo M
    Am J Transl Res; 2023; 15(4):2568-2584. PubMed ID: 37193151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EOGT Correlated With Immune Infiltration: A Candidate Prognostic Biomarker for Hepatocellular Carcinoma.
    Shu Y; He L; Gao M; Xiao F; Yang J; Wang S; Wei H; Zhang F; Wei H
    Front Immunol; 2021; 12():780509. PubMed ID: 35069551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machado-Joseph Deubiquitinases: From Cellular Functions to Potential Therapy Targets.
    Zeng C; Zhao C; Ge F; Li Y; Cao J; Ying M; Lu J; He Q; Yang B; Dai X; Zhu H
    Front Pharmacol; 2020; 11():1311. PubMed ID: 32982735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AUNIP Expression Is Correlated With Immune Infiltration and Is a Candidate Diagnostic and Prognostic Biomarker for Hepatocellular Carcinoma and Lung Adenocarcinoma.
    Ma C; Kang W; Yu L; Yang Z; Ding T
    Front Oncol; 2020; 10():590006. PubMed ID: 33363020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
    Lu T; Li C; Xiang C; Gong Y; Peng W; Chen C
    Biomed Res Int; 2022; 2022():7823191. PubMed ID: 35313629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ANP32 Family as Diagnostic, Prognostic, and Therapeutic Biomarker Related to Immune Infiltrates in Hepatocellular Carcinoma.
    Liu X; He Y; Wang P; Hu J; Hao C; Wang Q; Yang Y; Sun Y; Ma B; Sun H; Xue D; Meng X
    Dis Markers; 2022; 2022():5791471. PubMed ID: 35280441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Over-expression of RRM2 predicts adverse prognosis correlated with immune infiltrates: A potential biomarker for hepatocellular carcinoma.
    Qin Z; Xie B; Qian J; Ma X; Zhang L; Wei J; Wang Z; Fan L; Zhu Z; Qian Z; Yin H; Zhu F; Tan Y
    Front Oncol; 2023; 13():1144269. PubMed ID: 37056349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma.
    Ma J; Jin J; Lu H; Zhang J; Li Y; Cai X
    Front Mol Biosci; 2022; 9():889414. PubMed ID: 35769911
    [No Abstract]   [Full Text] [Related]  

  • 19. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
    Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
    World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Therapeutic Targets and Prognostic Biomarkers among Genes from the Mediator Complex Family in the Hepatocellular Carcinoma Tumour-Immune Microenvironment.
    Tan W; Peng S; Li Z; Zhang R; Xiao Y; Chen X; Zhu J; Li B; Lv X
    Comput Math Methods Med; 2022; 2022():2021613. PubMed ID: 35069777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.